GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.16 USD
0.00 (-0.06%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $0.16 0.00 (1.01%) 7:08 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GLYC 0.16 0.00(-0.06%)
Will GLYC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GLYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLYC
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
GLYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GLYC
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)
GlycoMimetics Announces Strategic Review and Restructuring Plan
Lockheed Martin upgraded, L3Harris downgraded: Wall Street's top analyst calls
GlycoMimetics just downgraded at TD Cowen, here's why